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ABSTRACT
Telomere length, shape and function depend on a complex of six core telomere-
associated proteins referred to as the telosome or shelterin complex. We here 
demonstrate that the isoform β2 of the heregulin family of growth factors (HRGβ2) 
is a novel interactor of the telosome/shelterin complex in human telomeres. Analysis 
of protein-protein interactions using a high-throughput yeast two-hybrid (Y2H) screen 
identified RAP1, the only telomere protein that is conserved from yeasts to mammals, 
as a novel interacting partner of HRGβ2. Deletion analysis of RAP1 revealed that 
the linker domain, a region previously suggested to recruit negative regulators of 
telomere length, interacts specifically with HRGβ2. Co-immunoprecipitation and 
imaging experiments demonstrated that, in addition to RAP1, HRGβ2 could associate 
with the RAP1-associated telomeric repeat binding factor 2 (TRF2). Deletion analysis 
of HRGβ2 confirmed that a putative nuclear localization signal (NLS) was necessary 
for nuclear HRGβ2 to exert a negative regulation of telomere length whereas the 
N-terminus (extracellular) amino acids of HRGβ2 were sufficient to interact with 
RAP1/TRF2 and promote telomere shortening. Taken together, our studies identify 
nuclear HRGβ2 as one of the previously unknown regulators predicted to be recruited 
by the RAP1 linker domain to negatively regulate telomere length in human cells. 
Our current findings reveal that a new, but likely not the last, unexpected visitor has 
arrived to the “telosome/shelterin town”.
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INTRODUCTION
Telomeres are specialized DNA-protein complexes 
found at the ends of eukaryotic linear chromosomes 
that provide protection from degradation, fusion, and 
recombination [1, 2]. Telomere homeostasis requires the 
cooperation between the DNA polymerase, telomerase, 
and an array of telomere end-binding factors including 
TRF1, TRF2, TIN2, RAP1, TPP1, and POT1. This 
complex, formed by multiple telomeric proteins with 
exquisite specificity for the arrays of telomerase-added 
TTAGGG repeats at chromosome ends, is known as the 
telosome or shelterin complex [3, 4]. Given the variety of 
functions that the telosome/shelterin complex performs, 
it is anticipated that the number of its affiliated factors 
will increase [3-5]. Accordingly, this complex of six core 
DNA-binding proteins and their sub-complexes serve 
as basic building blocks from which diverse signaling 
pathways originate through coordination of protein-
protein interactions and protein complex cross-talk on the 
telomeres, the so-called telomere “interactome” [6-8].
The heregulin (HRG) family of growth factors 
comprises 15 distinct isoforms originating from alternative 
RNA splicing of HRG1, HRG2, HRG3, and HRG4 genes. 
HRG plays an important role in human cancer through 
its conventional paracrine or autocrine ability to bind 
and activate the HER-2/-3/-4 (erbB-2/-3/-4) tyrosine-
kinase cell surface receptors [9-13]. Focusing on the 
isoform HRGβ2, our previous studies in mice have shown 
that HRGβ2 overexpression, independent of estrogen 
stimulation or high levels of the HER2 (erbB-2) oncogene, 
is sufficient for the generation of adenocarcinomas 
while favoring the metastatic spread of breast cancer 
(BC) cells [14, 15]. Conversely, antisense blockade of 
HRGβ2 expression efficiently inhibits tumorigenesis 
and metastasis in BC cells [16]. Therefore, HRGβ2 can 
exclusively promote cell malignant transformation, 
tumorigenicity and metastasis. Moreover, HRGβ2 can 
differentially modulate BC cell responses to DNA-
damaging drugs. Accordingly, forced expression of 
HRGβ2 promotes cancer cell hypersensitization to the 
anthracycline antibiotic doxorubicin while inducing 
resistance to the alkylating agent cisplatin [17-19]. 
Interestingly, some HRGs have been shown to translocate 
to the nucleus in cancer cells, strongly suggesting that 
the activity HRGβ2 is not confined to the initiation of 
surface receptor-mediated signaling [18, 20-23]. It is not 
clear, however, which functions of HRGβ2 are exclusively 
dependent on the activation of erbB receptors, which can 
be solely attributed to its nuclear compartmentalization, 
and which HRGβ2 domains might serve to link a distinct 
sub-cellular localization of HRGβ2 with a given function 
in cancer cells. 
Using the yeast two-hybrid (Y2H) system as a high-
throughput platform for interactomics, we here aimed to 
investigate HRGβ2 protein-interaction networks. Using 
the classical screen to search for pairwise interactions 
between HRGβ2 and putative interaction partners present 
in a human mammary gland cDNA library, we provide the 
first demonstration that HRGβ2 is a novel interactor of 
the telosome/shelterin complex that connects the linker 
domain of repressor-activator protein 1 (RAP1) [24], a 
region suggested to recruit negative regulators of telomere 
length, with the RAP1-associated factor TRF2 [24-27]. 
RESULTS 
Yeast two-hybrid screening reveals an association 
between HRGβ2 and the telomeric protein RAP1
To identify new protein interacting partners of 
HRGβ2, we fused cDNA corresponding to the full-length 
coding sequence of human HRGβ2 to the GAL4-DNA-
Binding Domain (GAL4-DBD) in pGBKT7 as bait in the 
Y2H system to screen a human mammary gland cDNA 
library. From a total of 35 positive transformants, only two 
transformants included open reading frames (ORFs) for 
known genes. Strikingly, both candidates were found to 
encode for telomere-related proteins. Positive clone #415 
contained DNA coding for amino acid residues 116-221 
at the C-terminal serine/arginine-rich domain of SC-35 
(gi:33875326), a human splicing factor that has been 
detected in close proximity to telomeres [28]. Positive 
clone #480 contained a 1.2 kb insert. Amplification of this 
insert by 5´-RACE resulted in a cDNA fragment encoding 
amino acid residues 127-259 of RAP1 (gi:8102032; 
Fig. 1A), a negative regulator of telomere length that 
specifically interacts with the telomere-associated protein 
TRF2 [3, 24-27, 29, 30]. 
In light of these observations and because of our 
recent novel finding that HRGβ2 is a new regulator of 
telomere length, likely through its ability to regulate 
and interact with TRF2 and RAP1 [31], we undertook 
a systematic approach to better understand the role of 
HRGβ2 at the telosome/shelterin complex in human 
telomeres. To confirm the direct interaction between 
HRGβ2 and RAP1, we transformed yeast with the 
full-length HRGβ2 ORF in the pGADT7 vector and a 
pACT2 plasmid expressing the full length RAP1 cDNA. 
Significant yeast growth was observed in plates containing 
selection medium (data not shown) indicating of an 
interaction between HRGβ2 and RAP1, and transformants 
were positive in the β-galactosidase assay (Fig. 1B). 
The linker domain of RAP1 mediates the 
interaction between RAP1 and HRGβ2
RAP1 contains four distinct functional domains: a 
BRCT domain, a Myb HTH motif, a coiled region, and 
a C-terminal protein interaction domain (termed RCT). 
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Figure 1: Y2H mapping of the region of RAP1 that interacts with HRGβ2. A. Sequencing analysis of a yeast two-hybrid 
screen using full-length HRGβ2 cDNA in the pGBKT7 vector and the human mammary gland Matchmaker cDNA library in the pACT2 
vector revealed that RAP1 interacts strongly and in a domain-specific manner with HRGβ2. B. Yeast was co-transformed with plasmids 
encoding 1) a fusion protein between the GAL4 activation domain and full-length or deletion hRap1 constructs, and 2) a fusion protein 
between the pGBKT7 DNA-binding domain and full-length HRGβ2. Representative β-gal activity (indicated by a blue color) and growth on 
plates containing selective medium in the yeast two-hybrid assay are presented at the right of the scheme. ++ indicates strong interaction, 
+/- normal to weak interaction, and – no interaction. BRCT, Myb, Link, Coil, and RCT are RAP1 domains. C. RAP1 interacts with HRGβ2 
at amino acids 127 through 259, specifically at the linker domain. 
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This structural architecture has been proposed to function 
as a protein adaptor, bringing different factors into the 
telomeric complex [24, 25, 29, 30]; for example, the RCT 
domain of RAP1 interacts with TRF2 and tethers RAP1 
to telomeres. Moreover, deletion analysis of RAP1 has 
suggested that the BRCT and Myb domains, as well as a 
novel linker region, may modulate the recruitment of one 
or more protein factors, which together are required for the 
execution of negative telomere length control [24, 25, 29, 
30]. To further characterize the interaction between RAP1 
and HRGβ2, we generated deletion mutants lacking each 
of the four functional domains or the linker region, and 
used these in the Y2H system. Deletion of the RCT or the 
BRCT domain did not significantly affect the interaction 
with HRGβ2 (Fig. 1B). In contrast, deletion of either 
the coiled region or the Myb domain evidently reduced 
the interaction between RAP1 and HRGβ2. Importantly, 
no interaction with HRGβ2 was observed with the 
RAP1 construct deficient for the linker region (Fig. 
1B). Therefore, while the BRCT and Myb domains of 
RAP1 are not sufficient to bind HRGβ2, the RAP1 linker 
domain appears to be essential. These results together 
with the sequencing data from the Y2H screen indicate 
that HRGβ2 might constitute a novel interactor of the 
telosome/shelterin complex through its interaction with 
RAP1 downstream of the BCRT domain, likely between 
amino acids 127 and 259 (Fig. 1C).
The N-terminal residues of HRGβ2 are sufficient 
to interact with RAP1 in cell nuclei
To verify the interaction between HRGβ2 and RAP1 
in vivo, we first characterized the nuclear translocation 
ability of HRGβ2, which has been demonstrated for 
other HRG isoforms [21-23]. We transiently transfected 
MCF-7 BC cells with a mammalian expression plasmid 
encoding EGFP-tagged full-length HRGβ2 or the empty 
pEGFP-C2 vector and examined the distribution of EGFP 
Figure 2: GFP-HRGβ2 and GFP-HRGβ2∆EGF colocalize with RAP1 in MCF-7 breast cancer cells. MCF-7 breast cancer 
cells were transiently transfected with GFP-HRGβ2 (top, green) or with GFP-HRGβ2∆EGF (bottom, green) and were stained with an 
anti-RAP1 antibody (red). Colocalization of merged images is indicated in yellow, and DAPI staining (blue) indicates nuclear DNA. 
The schematic domains of HRGβ2 constructs are shown. Full-length HRGβ2 directs GFP to cytoplasmic membrane, peri-nuclear region, 
nucleolar-like structures and nuclear speckles. In a significant proportion of cells, the full-length form of HRGβ2 targets GFP to nuclear 
speckles, as shown in top panels. Merged images revealed co-localization (yellow) of GFP-tagged full-length HRGβ2 with RAP1 in many 
nuclear speckles. Deleting the EGF-like, the transmembrane and the cytoplasmic domains of HRGβ2 prevented the localization of HRGβ2 to 
cytoplasmic membrane, peri-nuclear region and nucleolar-like structures. GFP-tagged HRGβ2∆EGF was targeted to nuclear speckles only 
in 100% of transfected cells. Co-staining with anti-RAP1 antibody revealed that the N-terminus residues of HRGβ2, which are sufficient to 
direct the GFP tag to nuclear speckles, strongly co-localize with RAP1. 
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by fluorescence microscopy after 24 h. In contrast to 
control cells, which had a uniform distribution of GFP 
throughout the cytoplasm (results not shown), GFP-
HRGβ2-transfected MCF-7 cells showed localization of 
the GFP signal to distinct cellular compartments including 
cytoplasmic membrane, peri-nuclear region, nucleolar-like 
structures and nuclear speckles (Fig. 2, top). Importantly, 
immunostaining with an anti-RAP1 antibody demonstrated 
that GFP-HRGβ2 concentrated at nuclear speckles, mostly 
co-localizing with native RAP1 (Fig. 2, top). 
To narrow down the sequence necessary for the 
nuclear import and sub-nuclear localization of HRGβ2, 
we constructed several deletion mutants of GFP-HRGβ2 
(unpublished data). We found that 100% of the cells 
transfected with an HRGβ2-derived construct lacking 
the EGF-like, the transmembrane and the cytoplasmic 
domains (HRGβ2-∆EGF), exhibited staining at nuclear 
speckles only (Fig. 2, bottom). Moreover, the speckled 
distribution pattern of GFP/HRGβ2-∆EGF completely 
co-localized with endogenous RAP1 immunostaining 
(Fig. 2, bottom). Together, these results confirm that 
HRGβ2 appears to interact with RAP1 at cell nuclei and 
further reveal that the N-terminal residues of HRGβ2 are 
sufficient for strong co-localization with RAP1, whereas 
the C-terminal region of HRGβ2 is dispensable for RAP1 
binding. 
HRGβ2 forms a protein complex with RAP1 in 
vivo
To bolster our findings that HRGβ2 and RAP1 form 
a protein complex in vivo, we next performed indirect 
immunofluorescent studies and co-immunoprecipitation 
assays in MDA-MB-231 and Hs578T BC cells, two 
metastatic cancer cell models that naturally overexpress 
HRGβ2 [16]. Consistent with our results using GFP-
tagged HRGβ2 protein in HRGβ2-negative MCF-7 cells, a 
Figure 3: HRGβ2 co-localizes and co-immunoprecipitates with RAP1 and the RAP1-interacting partner TRF2 in 
breast cancer cells. Representative immunofluorescent images of MDA-MB-231 and Hs578T cells co-stained for endogenous HRGβ2 
(green) and A. RAP1 (red) or B. TRF2 (red) are shown (n = 3). Merged images indicate co-localization (yellow). DAPI was used to 
visualize nuclear DNA (blue). Endogenous HRGβ2 was immunoprecipitated from MDA-MB-231 or Hs578T nuclear extracts with pre-
immune serum (PI) or a polyclonal anti-HRGβ2 antibody (HRGβ2 IP) in the absence (-) or presence (+) of a blocking HRGβ2 peptide (BP). 
Precipitates were separated by SDS-PAGE, transferred to nitrocellulose, and probed with antibodies against A. RAP1 or B. TRF2. One 
representative immunoblot is shown (n = 3). 
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prominent sub-nuclear localization of endogenous HRGβ2 
was observed in MDA-MB-231 and Hs578T cells (Fig. 
3A, left panels). Immunostaining with an anti-RAP1 
antibody further confirmed that the punctuate distribution 
pattern of endogenous HRGβ2 significantly co-localized 
with endogenous RAP1 (Fig. 3A, left panels). This co-
distribution of HRGβ2 and RAP1 occurred throughout 
the nuclei in essentially all cells, suggesting a lack of 
dependence on cell cycle status. 
Nuclear extracts from MDA-MB-231 and Hs578T 
cells were immunoprecipitated with protein A/G beads 
coupled to an anti-HRGβ2 antibody. After elution, the 
purified proteins were analyzed by immunoblotting using 
an anti-RAP1 antibody, and compared to crude nuclear 
extracts or an immunoprecipitate from a non-specific 
antibody. Western blot analyses of proteins released from 
the beads revealed that RAP1 co-immunoprecipitated 
with HRGβ2 (Fig. 3A, right panels). This association was 
specific since no RAP1 was recovered with a pre-immune 
serum; moreover, HRGβ2-RAP1 co-immunoprecipitation 
was fully prevented in the presence of a competing peptide 
directed against the sequence from which the anti-RAP1 
antibody was raised (Fig. 3A, right panels). 
Figure 4: Nuclear HRGβ2 negatively regulates telomere length in breast cancer cells. A. Left. Representative immunoblot 
showing shRNA-mediated knockdown of HRGβ2 in MDA-MB-231 cells. Right. Flow-FISH analysis of cells in the G0/G1 phase was 
performed using a telomere-specific probe as described in the “Materials and methods” section. (-) and (+) indicate Flow-FISH analysis in 
the absence or presence, respectively, of the telomeric probe. Bivariate cytograms indicate the telomere length in each sub-compartment 
of the cell cycle. The histograms show the telomere length within the G0/G1 cell subpopulation, where the cells have only one copy of the 
genome. Telomere length is expressed in relative fluorescence units (mean ± SD) of four independent experiments. B. MCF-7 cells were 
transiently transfected with GFP-HRGβ2 or GFP-HRGβ2ΔNLS, and telomere length was analyzed by Flow-FISH as described above (n 
= 3). C. MCF-7 cells were stably transduced with either pBABE retroviral vector alone or pBABE containing cDNA for HRGβ2ΔNLS (a 
structural mutant of HRGβ2 that lacks the putative NLS), HRGβ2ΔEGF (a structural mutant of HRGβ2 that cannot bind HER3 or HER4 
receptors), or for full-length HRGβ2 as specified. Telomere length was assessed by Southern blot analysis of HinfI/RsaI–digested genomic 
DNA as described in the “Materials and methods” section. Molecular weight (MW) markers (black bars, in kb) and mean terminal restriction 
fragment lengths (TRFL; red bars) are indicated. 
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HRGβ2 interacts with the RAP1 partner TRF2
Having established a physical interaction between 
HRGβ2 and RAP1 in the nuclei of human cancer cells, 
we next questioned whether HRGβ2 might also interact 
with the RAP1 partner TRF2. Similar to previous findings, 
endogenous TRF2 was found to exhibit a punctuated 
pattern in the nuclei of MDA-MB-231 and Hs578T cells, 
as demonstrated by immunofluorescent staining (Fig. 3B, 
left panels). More importantly, native TRF2 significantly 
co-localized with endogenous HRGβ2 (Fig. 3B, left 
panels). Furthermore, co-immunoprecipitation analysis in 
MDA-MB-231 and Hs578T cells specifically showed that 
TRF2 and HRGβ2 co-precipitate since this interaction was 
abolished in the presence of an HRGβ2-derived blocking 
peptide (Fig. 3B, right panels). This association between 
HRGβ2 and RAP1/TRF2-containing protein complexes 
was not due to tethering by nucleic acids since the addition 
of ethidium bromide to nuclear extracts during the 
preclearance step and the immunoprecipitation reaction 
did not affect the recovery of RAP1 and TRF2 from the 
HRGβ2 immunoprecipitation (data not shown). 
Nuclear localization of HRGβ2 is necessary for 
HRGβ2-driven regulation of telomere length
Our discovery of the importance of the linker 
domain of RAP1, a region previously suggested to 
recruit negative regulators of telomere length [24-27], is 
consistent with recent findings from our group showing 
that the proteinaceous link between HRGβ2, TRF2, 
and RAP1 might explain HRGβ2’s ability to negatively 
regulate telomere length [31]. We therefore investigated 
whether the nuclear co-localization of HRGβ2 with the 
RAP1/TRF2 complex was required for HRGβ2-driven 
regulation of telomere length. We first needed to confirm 
that HRGβ2 is a novel regulator of telomere length 
[31]. Using fluorescent in situ hybridization (FISH) 
with labeled peptide nucleic acid (PNA) probes specific 
for telomere repeats, in combination with fluorescence 
measurements by flow cytometry (flow FISH), we 
verified that transient shRNA-driven knockdown of 
HRGβ2 expression was sufficient to rapidly promote 
significant lengthening of telomeres in the highly-
aggressive, HRGβ2-overexpressing MDA-MB-231 BC 
cell line (Fig. 4A). We then evaluated whether the minimal 
structural requirements for HRGβ2 nuclear translocation 
determined its ability to regulate telomere length. We 
identified a putative nuclear localization signal (NLS) in 
the N-terminus (extracellular domain) of HRGβ2, between 
amino acids 4 and 16. To test the functionality of this 
region, we deleted the first 33 amino acids of the HRGβ2 
cDNA containing this putative NLS and analysed HRGβ2 
nuclear translocation. Indirect immunofluorescence of 
MCF-7 BC cells transiently transfected with the GFP/
HRGβ2-∆NLS fusion expression plasmid revealed that 
the deletion of the NLS domain completely prevented 
its transport to the nucleus. Accordingly, a striking peri-
nuclear accumulation of GFP/HRGβ2-∆NLS was clearly 
seen in most cases in transfected cells, in comparison with 
the prominent nuclear speckles observed with transfected 
full-length HRGβ2 protein (Fig. 4B). Importantly, whereas 
MCF-7 cells transiently transduced to express high levels 
of full-length HRGβ2 exhibited telomere shortening as 
revealed by a significantly lower telomeric fluorescence 
intensity on Flow-FISH analyses, we failed to observe 
significant changes in the telomere length of MCF-7 cells 
transiently transduced to express high levels of HRGβ2 
lacking the NLS sequence (Fig. 4B). To complement this 
finding, we analyzed telomere length by pulse-field gel 
analysis of digested genomic DNA followed by Southern 
blot hybridization using a telomere-specific probe. In 
MCF-7 cells stably overexpressing either full length 
HRGβ2, HRGβ2-∆NLS or HRGβ2-∆EGF constructs, 
we found that the nuclear localization of HRGβ2 was 
necessary to promote telomere shortening, and the 
N-terminal (extracellular) amino acids of HRGβ2 are 
sufficient to promote this effect (Fig. 4C). 
DISCUSSION
A growing number of growth factors such as 
FGF, amphiregulin and PDGF have been identified 
in the nucleus [32-36]. The biological implications of 
such localizations, however, are not well understood 
and remain contentious. We show for the first time that 
HRGβ2 unexpectedly functions as an interactor of the 
telosome/shelterin complex in the nucleus by virtue of 
its direct interaction with RAP1, a negative regulator of 
telomere length that associates with telomeres primarily 
through its interaction with the telomere-binding protein 
TRF2. Specifically, the region of RAP1 that interacts with 
HRGβ2 necessarily involves its linker region. Earlier 
studies showed that a RAP1 mutant lacking this region 
was incapable of extending telomeres, and results from 
deletion analyses suggested that the linker region could 
modulate the recruitment of putative negative regulators 
of telomere length [24, 25, 29, 30]. Consistent with these 
findings, we found that changes in HRGβ2 expression and 
sub-cellular compartmentalization were concomitant with 
rapid and detectable alterations in telomere length, thus 
supporting the notion that HRGβ2 acts as a previously 
unrecognized negative regulator of telomere length and is 
recruited by the linker domain of RAP1. 
How might HRGβ2 regulate telomere length? It has 
been described that expression of a RAP1 mutant lacking 
the linker region reduced the number of TRF2 foci in cells. 
This result suggests that while the RAP1-∆linker construct 
was still able to interact with TRF2, it may disrupt the 
interaction of TRF2 with the telomere and, consequently, 
lead to a reduction in average telomere length [29, 30]. 
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Alternatively, the linker domain might be also involved 
in the recruitment of yet unidentified negative regulators 
of telomere length. Because our findings reveal that 
HRGβ2 is not a core component but rather an accessory 
factor of the telosome/shelterin complex, the ability of 
HRGβ2 to simultaneously co-interact with RAP1 and 
TRF2 may reconcile these two hypotheses. Suppression 
of HRGβ2 expression or prevention of its efficient 
nuclear translocation might uncouple the RAP1/TRF2 
complex from sequestering the telomere ends and allow 
access of telomerase to its substrate. Conversely, HRGβ2 
overexpression or nuclear accumulation of HRGβ2 might 
promote the stabilization of the RAP1/TRF2 complex at 
the chromosome ends, thus leading to telomere shortening. 
In line with this concept, we found that forced expression 
of HRGβ2 in HRGβ2-negative BC epithelial cells is 
sufficient to induce the up-regulation and the stabilization 
of RAP1/TRF2 complexes while coincidentally promoting 
telomere shortening. Knockdown of HRGβ2, however, 
decreases the abundance of TRF2 and RAP1 proteins 
and reduces their telomeric content while concomitantly 
inducing telomere lengthening [31]. These RAP1/TRF2-
related telomere-regulating actions of HRGβ2 recapitulate 
the features found by deleting the linker region of RAP1 
[24]. Since most if not all TRF2 is in a complex with 
RAP1, it is reasonable to suggest that HRGβ2 might 
function as a direct interacting partner for stable binding 
between RAP1 and TRF2. In this scenario, HRGβ2 
Figure 5: HRGβ2: A novel interactor of the telosome/shelterin complex. A. Data reported by Li & Lange [30] and O’Connor 
et al. [24] originally suggested that RAP1 is a negative regulator of telomere length and that the BRCT, linker and/or Myb domains were 
required for this regulatory function. It was proposed that these RAP1 domains should interact with a factor(s), i.e., either three different 
proteins, X, Y, and Z, or different domains of the same protein(s), which will be required for negative regulation of telomere length. Our 
current mapping of the interacting regions between RAP1 and HRGβ2, together with the sequencing data from the Y2H screen, reveal that 
HRGβ2 is a novel interactor of the telosome/shelterin complex through its interaction downstream of the BRCT domain of RAP1, likely 
between amino acids 127 and 259. HRGβ2 should be viewed as one of the unknown negative regulators of telomere length recruited by 
the linker domain of RAP1 that, in addition, simultaneously interacts with the RAP1 partner TRF2. B. The delineation of the 6 telomeric 
proteins (TRF1, TRF2, TIN2, RAP1, TPP1, and POT1) and their associated partners has provided the basis for constructing an interaction 
map of telomere regulators in mammalian cells, the so-called telomere interactome [6-8], which represents the molecular machinery that 
controls mammalian telomeres and enables the integration of the various signaling pathways that regulate telomeres with other cellular 
interactomes. At the core of the telomere interactome is the telosome/shelterin complex, which can recruit a multitude of factors through 
various telosome subunits (e.g., RAP1) and mostly through protein hubs, which mediate multiple interactions with other proteins in the 
telomere interactome consistent with their key roles in telomere control (e.g., TRF2). Because TRF2 directly binds telomere DNA and 
recruits different proteins that are involved not only in cell cycle, DNA repair and recombination but also in end protection (e.g., RAP1) 
[6-8, 55], the ability of HRGβ2 to interact with RAP1 and TRF2 strongly suggest that HRGβ2 may significantly alter the protein-protein 
interaction within the telomere interactome to regulate telomere function and dynamics in normal development or in diseased cells, such as 
cancer and aging cells. Whether the RAP1-HRGβ2-TRF2 interaction actually determines whether the telomerase complex can be recruited 
or displaced from the core of the telosome/shelterin complex and/or whether TRF2 can efficiently remodel the telomere end into t-loop 
structures [55], which sequester and protect the ends of chromosomes, remains to be determined. 
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could function to modulate correct telomere tethering of 
this telosome/shelterin complex subunit and, ultimately, 
regulate telomere homeostasis maintenance (Fig. 5A). 
Our current findings revealing the telomere-related 
“intracrine” functioning of HRGβ2 supports the concept 
that, in a counterintuitive manner, secreted growth factors 
such as the HRG family, can promote highly specific 
actions in defined cellular compartments. This discovery 
adds even more complexity to the “import(ance) of 
growth factors in(to) the nucleus” [32-36] and may have 
significant implications in our molecular understanding 
of the natural history of age-related pathologies including 
cancer. Indeed, our current findings provide molecular 
support to our “telomere-dependent” hypothesis, 
integrating epithelial BC, aging stroma and cellular 
senescence, by considering an unforeseen telosomic 
activity of HRG [37-40]. Earlier studies from our 
laboratory described how senescent human fibroblasts 
significantly stimulated hyperproliferation and progression 
of pre-neoplastic breast epithelial lesions and accelerated 
the tumorigenic capacity of neoplastic breast epithelial 
cells [41]. The BC-promoting activity of senescent cells 
was likely due to the secretory phenotype of senescent 
fibroblasts, which is characterized by changes in the 
expression of cell type-specific genes [39, 42, 43]. While 
acknowledging that the critical factor(s) produced by 
aging –senescent- stroma for the stimulation of pre-
cancerous and cancerous breast epithelial lesions remains 
an unanswered question, it is relevant to note that HRG 
is one of the major growth factors secreted by senescent 
fibroblasts [42, 44]. Beyond the well-characterized 
autocrine/paracrine activating actions of HRG on the 
erbB network-driven signaling, its intracrine regulation of 
telomere-dependent genome stability may provide a key 
rate-limiting step in breast carcinogenesis and metastatic 
progression. Short telomeres have been shown to 
generate chromosome instability, which in turn may lead 
to an increased risk of several cancers including breast 
carcinoma [45-47]. As an illustration, we now know that 
transition through telomere crisis and immortalization is 
a crucial event in BC that occurs during progression from 
typical ductal hyperplasia to pre-invasive ductal carcinoma 
in situ (DCIS), as well as in focal areas of histologically-
normal epithelium from which breast carcinoma is thought 
to arise [48, 49]. In this scenario, an HRG-induced 
shortening of telomeres in breast epithelial cells, as an 
additional driver of chromosome destabilization in the 
early stages of breast tumorigenesis, may molecularly link 
the tumorigenic role of HRG-overproducing senescent 
cells at sites of age-related pathologies such as BC. Indeed, 
a reduced telomeric DNA content correlates with genomic 
instability and metastasis in invasive breast carcinomas 
[50, 51]. Remarkably, pro-metastatic HRG proteins have 
recently been found to significantly accumulate not only 
in cell nuclei of invasive breast carcinomas but also in 
DCIS, whereas no nuclear HRG is found in normal tissues 
[22, 52]. Therefore, it is reasonable to suggest that some 
cancer promoting actions of the aging stroma can rely, at 
least in part, on its ability to secrete enormous amounts of 
HRG which, in turn, will trigger and maintain telomere 
shortening in the breast epithelial compartment in a RAP1/
TRF2-dependent manner. 
The elucidation of the interaction and function of 
the core proteins TRF1, TRF2, RAP1, TIN2, POT1, and 
TPP1 within the telosome/shelterin complex has allowed 
a better understanding of the molecular intricacies that 
ultimately regulate telomere end-capping and length 
control. It is now known that the telosome/shelterin 
complex forms the basic platform on which layers of 
telomere signaling networks can be assembled onto the so-
called telomere interactome [6, 7] for the proper protection 
and maintenance of mammalian telomeres. Considering 
the ever-growing list of proteins that integrate the complex 
and labyrinthine network of the telomere interactome, one 
can wonder “how there is even room” for new regulators 
at chromosome ends [53, 54] (Fig. 5B). Our study refines 
the current appreciation of the telomere interactome by 
incorporating the nuclear version of the growth factor 
HRG as a constituent of the various telomere-signaling 
pathways and telomere-associated molecular machinery 
that regulate mammalian telomeres. Future studies are 
warranted to explore in detail the function of HRG at 
telomeres and to dissect the mechanisms by which HRG 
communicates with the telosome/shelterin complex core 
to coordinate different cellular signaling pathways for 
telomere maintenance including cell cycle, telomere 
length, end protection or DNA repair in cancer and aging. 
Our current findings reveal that a new, but likely not the 
last, unforeseen player has been added to the “telosome/
shelterin town”.
MATERIALS AND METHODS
Cloning of HRGβ2
Poly (A) RNA was extracted from HRGβ2-
overexpressing MDA-MB-231 BC cells using the Oligotex 
Direct mRNA Kit (Qiagen). Three µg of poly (A) RNA 
was reverse transcribed and amplified using the Gene Amp 
RNA PCR Kit (Applied Biosystems). To obtain the entire 
ORF of HRGβ2, the digested PCR product was cloned into 
the pRcCMV plasmid (Met1 to Ser422) using the BSU361 
and XbaI sites. The region encoding the C-terminal 
domain of HRGβ2 (Phe401 to Val636) was amplified 
using primers 5’- TCAGGCATGCCAGAGAAACC-3’ 
and 5’-ATTATACAGCAATAGGGTCTTGGTT-3’.
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Yeast two-hybrid assay
The yeast two-hybrid assay was performed 
according to the Matchmaker Gal4 two-hybrid system 3 
manual (CLONTECHniques). The yeast strain AH109 
containing ADE2, HIS3, lacZ, and MEL1 reporter genes, 
each of which uses a distinct GAL4-responsive promoter, 
was used in the assay. These distinct promoter elements 
automatically eliminate three major categories of false 
positives: those caused by proteins that interact upstream 
of the reporter construct binding site, those that interact 
directly with the sequences flanking the GAL4 binding 
site, and those that interact with transcription factors 
bound to specific TATA boxes. The entire HRGβ2 ORF was 
sub-cloned in frame into the DNA-Binding Domain (BD) 
vector pGBKT7. The pGBKT7-HRGβ2 bait vector and 
the human mammary gland Matchmaker cDNA library in 
the pACT2 vector were co-transformed into strain AH109 
and grown on minimal synthetic medium lacking Ade, 
His, Leu and Trp to test potential interactors. The HRGβ2 
bait did not have any intrinsic activity of transcriptional 
activation for the reporters (data not shown). The X-α-Gal 
(5-Bromo-4-chloro-3-indolyl-α-D-galactopyranoside) 
indicator was included to screen transformants. 
Approximately 1 x 106 independent transformants 
were pooled and re-plated on selection media (Ade-, His-, 
Leu- and Trp-) containing 2% galactose (Gal) to induce the 
expression of cDNAs. In total, 35 transformants showed 
Gal-dependence in the selction medium. Plasmids from 
these transformants were extracted by yeast mini-prep 
and the cDNAs were amplified in the PCR with primers 
derived from the pJG4-5 vector, followed by sequence 
determination. To eliminate false positive, we performed 
separation and isolation of yeast plasmids followed by 
propagation in bacteria. This approach revealed that: 1 
clone was not in frame with GAL4, 6 clones included 
3’ untranslated regions (UTRs), while 24 clones were 
found to be artifactual positive yeast clones. The two truly 
positive clones including ORFs for known genes were 
found to encode for the telomere-related proteins SC-35 
and RAP1 (see text).
Mapping of the interacting domains of RAP1 and 
HRGβ2. AH109 cells were co-transformed with plasmids 
encoding a fusion protein between the GAL4 activation 
domain (AD) and full-length RAP1 (pACT2-hRap1, a 
gift from Dr Titia de Lange), or RAP1 deleted constructs 
and a plasmid encoding a fusion protein between full-
length HRGβ2 and the DNA-BD included in pGBKT7, 
using a small-scale LiAc/ssDNA/PEG transformation 
protocol. RAP1 truncations were generated by PCR as 
described (24): hRap1 (full-length, amino acids 1-198), 
∆Myb (amino acids 1-132 and 192-399), ∆Link (amino 
acids 1-198 and 224-399), ∆RCT (amino acids 1-290, with 
an N-terminal nuclear localization signal PRRK), ∆R∆C 
(∆RCT/∆Coil-Coil, amino acids 1-227, with an N-terminal 
nuclear localization signal PRRK), and ∆BRCT (amino 
acids 129-399). Transformants were plated onto 
appropriate minimum synthetic dropout media and then 
tested for β-galactosidase activity. 
Generation and visualization of GFP-HRGβ2
A full length HRGβ2 enhanced green fluorescent 
protein (EGFP) fusion construct was engineered by 
removing the HRGβ2 insert from pGBKT7/HRGβ2 with 
EcoRI and BamHI and cloning into the equivalent sites 
of pEGFP-C2. Structural deletion mutants of HRGβ2 
were generated by PCR and cloned into pEGFP-C2 or 
pEGFP-N2 vectors digested with EcoRI and BamHI. 
MCF-7 cells were used for transient expression 
analysis of GFP-HRGβ2 constructs. Cells were grown 
on glass coverslips to 60%-80% confluence and were 
transfected for 6 hours with 1 µg plasmid DNA using 
FuGENE transfection reagent (Roche, Indianapolis, 
IN). Transfected cells were seeded on glass coverslips 
in six-well plates and incubated for 24 hours. Cells 
were fixed/permeabilized with 0.2% Triton X-100/2% 
paraformaldehyde and permeabilized again in 100% 
methanol for 10 minutes at -20 oC. Coverslips were 
blocked for 30 minutes at 37 oC in 5% BSA in phosphate-
buffered saline (PBS), incubated with a RAP1-specific 
antibody (1:200 dilution of IMG-272, Imgenex, San 
Diego, CA), washed, and incubated with Texas Red-
conjugated anti-mouse IgG. Coverslips were mounted with 
4,6-diamidino-2-phenylindole (DAPI) onto microscope 
slides. Cells were observed and analyzed using a Zeiss 
Axioskop microscope equipped for epifluorescence.
Fluorescence microscopy
MDA-MB-231 and Hs578T cells were grown 
on glass coverslips to 60%-80% confluence and fixed/
permeabilized/blocked as described above. Cells were 
then stained with HRGβ2-, RAP1- and/or TRF2-specific 
antibodies (1:100 dilution of the anti-HRGβ2 C20 antibody 
–sc-348-; Santa Cruz Biotech. Santa Cruz, CA and 1:200 
of anti-RAP1 or anti-TRF2 IMG-124 antibody, Imgenex, 
San Diego, CA) and then incubated with Texas Red-
conjugated anti-mouse IgG for hRap1 and TRF2 (red) 
and FITC-conjugated anti-rabbit IgG antibody for HRGβ2 
(green). 
Immunoprecipitation and western blotting
For co-immunoprecipitation (IP) analysis of HRGβ2 
and RAP1/TRF2, MDA-MB-231 and Hs578T cultures 
were expanded on 15-cm plates. At confluence, cells were 
trypsinized, collected in a10X pellet volume of PBS and 
lysed using the EZ Prep Nuclei Isolation Kit (Sigma-
Chemicals, St. Louis, MO). The purified nuclei were 
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resuspended in a 3X pellet volume in low salt nuclear 
extraction buffer [20 mmol/L Tris, pH 7.3, 20 mmol/L 
KCl, 25% glycerol, 1.5 mmol/L MgCl2, 0.2 mmol/L 
EDTA, 1X phenylmethylsufonyl fluoride, and a complete 
protease inhibitor mixture tablet]. An equal volume of 
high salt nuclear extraction buffer (1.2 M KCl, 20 mmol/L 
Tris, pH 7.3, 25% glycerol, 1.5 mmol/L MgCl2, 0.2 
mmol/L EDTA) was added and the nuclear extract was 
kept on ice for 30 min with occasional vortexing. The 
sample was then centrifuged at 14,000 rpm for 15 minutes 
and the supernatant was diluted with an equal volume of 
water. One mg of nuclear protein was pre-cleared using 
1.25 µg of rabbit IgG and 20 µL of A/G beads for 30 min 
at 4 oC (pre-immune –PI-). The supernatant was incubated 
for 2 hours with 1 µg of C-20 anti-HRGβ2 antibody (sc-
348; Santa Cruz Biotech.) in the absence or presence of 
an HRGβ2 blocking peptide. Twenty µL of A/G beads 
were added and the mixture was incubated overnight at 
4 oC. Ethidium bromide or RNase A was added to the 
nuclear extracts (both at a final concentration of 100 µg/
ml) during preclearance and throughout the IP procedure. 
Immunocomplexes were washed several times with NETN 
buffer [20 mmol/L Tris, pH 8.0, 100 mmol/L NaCl, 0.5% 
Nonidet P-40, 1 mmol/L EDTA), boiled in SDS loading 
buffer, separated on 10% SDS-PAGE gels and transferred 
to nitrocellulose membranes. Nonspecific binding was 
minimized by blocking the membranes for 1 hr at room 
temperature (RT) with TBS-T [25 mmol/L Tris-HCl, 150 
mmol/L NaCl, pH 7.5, and 0.05% Tween 20] containing 
5% (w/v) nonfat dry milk. The treated filters were washed 
in TBS-T and then incubated with anti-hRap1 and 
anti-TRF2 primary antibodies for 2 hr at RT in TBS-T 
containing 1% (w/v) nonfat dry milk. After a subsequent 
wash in TBS-T, horseradish peroxidase-conjugated 
secondary antibodies (Jackson Immunoresearch Labs, 
West Grove, PA) in TBS-T were added for 1 hr, and 
immunoreactive bands were detected by enhanced 
chemiluminescence reagent (Pierce, Rockford, IL). 
Generation of MCF-7 cells overexpressing full-
length HRGβ2 or HRGβ2 deletion mutants
The PCR products generated using the HRGβ2 
cDNA accession number 183996 (full length HRGβ2) 
or the structural deletion mutants (HRGβ2-∆NLS and 
HRGβ2-∆EGF) were cloned into the retroviral expression 
vector pBABE-Puro using BamHI and EcoRI restriction 
sites. Retroviral constructs were transfected into a high 
efficiency transient amphotropic packaging system 
(TSA54 cell line) with FuGENE reagent. Retrovirus-
containing medium collected after 48 h was used to 
infect MCF-7 cells for 24 h in the presence of Polybrene 
(Sigma-Chemicals). Infected MCF-7 cells were grown for 
an additional 24 hours in standard medium and stable cell 
lines (MCF-7/pBABE, MCF-7/HRGβ2, MCF-7/HRGβ2-
∆NLS and MCF-7/HRGβ2-∆EGF) were selected and 
expanded in the presence of 2.5 µg/mL puromycin for 
two weeks. Expression levels of HRGβ2, HRGβ2-∆NLS 
and HRGβ2-∆EGF were assessed by RT-PCR using the 
Gene Amp Kit (Promega Corporation). Alternatively, cells 
were transiently transduced with replication-incompetent 
amphotropic retroviruses containing either a full-length 
HRGβ2 cDNA construct or a HRGβ2-∆NLS deletion cDNA 
construct cloned in the pLXSN (LTR-gene X-simian virus 
40-Neo) retroviral expression vector (Clontech) in the 
presence of 4 µg/mL polybrene. Viruses were added at 
appropriate dilutions, and the cells incubated for 48 h to 
allow expression of the HRGβ2 or HRGβ2-∆NLS proteins 
from the integrated pLXSN vector. 
HRG gene silencing by small interfering RNAs
An siRNA duplex used for silencing the human HRG 
was purchased from Santa Cruz Biotech. Transfections 
were performed as described in the technical bulletin. 
Telomere analysis by fluorescence in situ 
hybridization and flow cytometry
Analysis of telomeres by flow cytometry using 
FISH was performed with a kit from DakoCytomation 
Denmark A/S (Glostrup, Denmark), Code No. K5327. 
Briefly, ∼ 2 x 106 cells were resuspended in 300 µL of 
hybridization buffer (70% deionized formamide, 10 
mmol/L Tris, pH 7.0, 10% fetal bovine serum, FBS) in the 
absence or presence of 0.3 µg/mL of the telomere-specific 
fluorescein isothiocyanate-conjugated probe (fluorescein 
isothiocyanate-O-CCCATAACTAAACAC-NH2). DNA 
from samples was heat-denatured for 10 minutes at 
82oC, followed by hybridization for 2 hours at RT. Cells 
were washed in wash buffer containing 70% deionized 
formamide, 10 mmol/L Tris, pH 7.0, 10% FBS and 0.1% 
Tween 20. After incubation for 1 hour at RT, cells were 
washed and resuspended in PBS, 10 % FBS, 10 µg/mL 
RNase A (Roche Molecular Diagnostics), and propidium 
iodide, incubated for 1 hour at RT, washed, and analyzed 
in a FACScalibur flow cytometer (Becton Dickinson). 
Cell Quest software (Becton Dickinson) was used for data 
acquisition and analysis. The telomere fluorescence signal 
was defined as the mean fluorescence signal in G0/G1 cells 
after subtraction of the background fluorescence signal 
(FISH procedure without probe). The flow cytometer was 
calibrated every day using fluorescein isothiocyanate-
labeled fluorescence Sphero microparticles (Pharmingen). 
The resulting calibration curve was used for correction 
of experimental fluorescence values in each experiment. 
Green fluorescence was measured in a linear scale, and 
results were expressed in molecular equivalents of soluble 
fluorochrome units (kMESF).
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Southern blotting analysis of Terminal Restriction 
Fragment (TRF) length
Cells from a sub-confluent 100-mm diameter 
culture dish were harvested by trypsinization, washed in 
cold PBS, collected by centrifugation for 5 min at 1,500 
rpm, and counted using the Coulter counter. Cell pellets 
were frozen at -80 oC until utilization. Genomic DNA was 
isolated from cell pellets (approximately 5 x 106 cells for 
each cell line) using a DNA extraction kit (Qiagen, Santa 
Clarita, CA) with inclusion of an RNase A digestion step, 
and quantitated with a spectrophotometer. Protein-free 
DNA was cleaved with HinfI and RsaI restriction enzymes 
(Gibco/BRL), extracted once with phenol/chloroform/
isoamyl alcohol, ethanol precipitated, and resuspended in 
Tris-EDTA to generate the TRF. A portion of DNA was 
subjected to electrophoresis in a 0.5% agarose gel in 1X 
Tris-Borate EDTA (TBE) buffer at 2 V cm-1 for 17 hours. 
The gel was dried at 60oC for 2 hours, denatured for 30-
60 minutes in 0.5 mol/L NaOH and 1.5 mol/L NaCl, and 
neutralized for 30-60 minutes in 1 mol/L Tris-HCl, pH 
8.0 and 1.5 mol/L NaCl. The dried gel was then subjected 
to in-gel hybridization with a [γ-32P]-ATP 5’ end-labeled 
oligonucleotide telomeric probe [γ-32P-(TTAGGG)3]. 
The autoradiography signal was digitized using a 
Phosphoimager (Amersham Biosciences) and Image-
QuaNT software (Molecular Dynamics). The mean size of 
the TRF was estimated using the formula L = E(ODi •Li)/ 
E(ODi), where ODi and Li were the signal intensity and 
TRF length, respectively, at position i on the gel image. 
This method takes into account the greater intensity of 
signals from larger fragments. Briefly, the scanned image 
was divided into a grid consisting of X columns and 
multiple rows where X were the number of samples. The 
rows were positioned to cover the entire vertical length of 
the image. The vertical size of grid boxes was arbitrary 
but it was small enough such that many boxes overlaid a 
signal smear. Two rows above and two rows below each 
signal smear were used to calculate the background. The 
background OD was averaged and then subtracted from 
the OD of each grid box to give the signal due to TRFs at 
that position. For each sample, OD and L were computed 
for each grid box, where OD was the total signal intensity 
within a grid box and L was the distance (in cm) at the 
mid-point of the grid box. Mean TRF length was then 
calculated using the above formula and values reported 
are the average of at least two independent Southern blots.
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